Baricent Tablet

Baricent Tablet 4 mg Introduction

Baricent Tablet 4 mg is a once-daily oral JAK (Janus-associated kinase) inhibitor approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). It is available as a film-coated tablet for oral administration and sold under the brand name Olumiant. Baricent Tablet 4 mg was developed by Eli Lilly and Incyte Corporation and is currently available in the United States, European Union, Japan, and other countries.

Uses for Baricent Tablet 4 mg

Baricent Tablet 4 mg is used to treat adult patients with moderately to severely active rheumatoid arthritis (RA), a type of arthritis which results in inflammation and pain in the joints. Baricent Tablet 4 mg can be used as monotherapy or in combination with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs).

Brand Name	Baricent
Type	Tablet
Weight	4 mg
Generic	Baricitinib
Manufacturer	Incepta Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Baricent Tablet 4 mg works by targeting JAK1 and JAK2, proteins which are part of the JAK-STAT signaling pathway. This pathway is important in the regulation of several processes, including inflammation. By inhibiting JAK1 and JAK2, Baricent Tablet 4 mg reduces the production of many inflammatory mediators and leads to a decrease in inflammation and pain associated with RA.

How Long Does It Take to Work?

The effects of Baricent Tablet 4 mg can be seen within 4 to 6 weeks of starting treatment. However it can take up to 4 months before the full therapeutic effects of Baricent Tablet 4 mg can be appreciated.

Absorption

Baricent Tablet 4 mg is quickly and completely absorbed from the gut following oral administration with peak plasma concentrations reached in 1 to 3 hours.

Route of Elimination

Baricent Tablet 4 mg is mainly eliminated through metabolism via CYP enzymes in the liver. The metabolites are then mainly eliminated through the faeces and to a lesser extent in the urine.

Dosage

Adult dose: The recommended dose of Baricitinib is 2 mg once daily. It may be used as monotherapy or in combination with Methotrexate or other Disease-modifying antirheumatic drugs (DMARDS). Baricitinib can be given orally with or without food.

Pediatric Use: The safety and effectiveness of Baricitinib in pediatric patients have not been established.

Geriatric Use: Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.

Hepatic Impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment.

Renal impairment: Baricitinib is not recommended for use in patients with estimated GFR of less than 60 mL/min/I .73 m2.

The recommended starting dose of Baricent Tablet 4 mg is 4 mg administered once daily. This dose can be reduced to 2 mg for patients who experience side-effects or to increase safety in certain populations.

Administration

Baricent Tablet 4 mg should be taken orally once a day with or without food. It should be administered in the morning or evening with the goal of evening administration in order to maintain a steady state of drug concentration in the body.

Side Effects

The most common side effects associated with Baricent Tablet 4 mg are nausea, upper respiratory tract infections, headache, and liver enzyme elevations.

Toxicity

In animal models, Baricent Tablet 4 mg was found to be well-tolerated with the no observed adverse effect level (NOAEL) much higher than the therapeutic dose in humans, indicating a wide margin between the toxic and therapeutic dose in humans.

Precaution

Patients should not take Baricent Tablet 4 mg if they have a known hypersensitivity to the active ingredient. It is also important to monitor for signs and symptoms of serious infections while taking Baricent Tablet 4 mg.

Interaction

Baricent Tablet 4 mg is metabolized mainly by CYP3A4 and to a lesser extent by CYP2C19. Therefore, caution should be exercised when taking other drugs which are also metabolized by these enzymes or which may interact with Baricent Tablet 4 mg in other ways.

Disease Interaction

Baricent Tablet 4 mg can increase the risk of serious infections in patients with chronic active infections or who have a history of recurrent infections. Therefore, caution should be used when prescribing Baricent Tablet 4 mg to such patients.

Drug Interaction

CYP3A4 inhibitors and inducers, such as oral hormonal contraceptives, antibiotics, antifungals, and HIV protease inhibitors, may interfere with the metabolism of Baricent Tablet 4 mg and increase its concentration in the blood. Such drugs should be avoided in patients taking Baricent Tablet 4 mg.

Food Interactions

It is recommended that Baricent Tablet 4 mg be taken either with food or without food. High-fat meals may reduce the absorption of Baricent Tablet 4 mg, while a high-fiber meal may increase it.

Pregnancy Use

There are no data from clinical studies on the use of Baricent Tablet 4 mg in pregnant women. However, pregnant women should not take Baricent Tablet 4 mg due to the potential risk of serious fetal harm.

Lactation Use

It is not known whether Baricent Tablet 4 mg is present in human milk. Therefore, it is not recommended for use in lactating women.

Acute Overdose

There is no specific antidote for an overdose of Baricent Tablet 4 mg. In cases of overdose, symptomatic and supportive measures should be taken in consultation with a poison control center.